• November 2008

      Integrated Cardiac Safety

      Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance

      by J. Rick Turner, Todd A. Durham

      The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug's cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary

    Subscribe to our newsletter